Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8700481 | 0.92 | CHRM1 (0.38) | CHRM1ALDH1A1MAPTNPSR1 | |
| SCHEMBL6780299 | 0.88 | SIGMAR1 (0.41) | CHRM1ALDH1A1 | |
| SCHEMBL8444907 | 0.77 | CHRM1 (0.42) | CHRM1ALDH1A1MAPTNPSR1 | |
| SCHEMBL7894532 | 0.77 | CHRM1 (0.42) | CHRM1 | |
| SCHEMBL8441881 | 0.77 | CHRM1 (0.42) | CHRM1ALDH1A1MAPTNPSR1 | |
| SCHEMBL8445611 | 0.77 | CHRM1 (0.42) | CHRM1ALDH1A1MAPTNPSR1 | |
| SCHEMBL8445481 | 0.72 | CHRM1 (0.39) | CHRM1ALDH1A1MAPTNPSR1 | |
| SCHEMBL11365244 | 0.68 | ALDH1A1 (0.34) | ALDH1A1MAPTNPSR1 | |
| SCHEMBL8074984 | 0.66 | CHRM1 (0.45) | CHRM1 | |
| SCHEMBL8319258 | 0.66 | CHRM1 (0.45) | CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1145364-A | Heterocyclic compounds and their preparation and use | LILLY CO ELI (US) | 1997-03-19 | — | — | CN | claimed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | claimed |
| US-6720342-B2 | AZABICYCLIC COMPOUNDS USED IN TREATING A DISEASE IN THE CENTRAL NERVOUS SYSTEM CAUSED BY MALFUNCTIONING OF THE MUSCARINIC CHOLINERGIC SYSTEM. | NOVO NORDISK A/S (DK) | 2004-04-13 | — | — | US | disclosed |
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | JEPPESEN LONE (DK) | 2002-08-22 | — | — | US | disclosed |
| EP-0900217-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| EP-0900219-A4 | HETEROCYCLIC COMPOUNDS | LILLY CO ELI (US) | 2001-05-23 | — | — | EP | disclosed |
| US-6187798-B1 | (+-)EXO-3-(3-(4-CHLOROPHENYL)PROPYNYLOXY-4-(1 -AZABICYCLO(2.2.1)HEPTYL-3-OXY)-1,2,5-THIADIAZOLE, FOR EXAMPLE; FOR MODULATING A MUSCARINIC RECEPTOR; TREATING ALZHEIMER'S DISEASE OR PSYCHOSIS | ELI LILLY AND COMPANY | 2001-02-13 | — | — | US | disclosed |
| US-6069159-A | USEFUL AS STIMULANTS OF THE COGNITIVE FUNCTION OF THE FOREBRAIN AND HIPPOCAMPUS OF MAMMALS | ELI LILLY AND COMPANY (US) | 2000-05-30 | — | — | US | disclosed |
| US-6040442-A | Process for preparing 1,2,5-thiadiazole containing ethers | ELI LILLY AND COMPANY (US) | 2000-03-21 | — | — | US | disclosed |
| CN-1048986-C | Heterocyclic compounds and their preparation and use | LILLY CO ELI (US) | 2000-02-02 | — | — | CN | disclosed |
| US-5998434-A | Composition for treating pain | ELI LILLY AND COMPANY (US) | 1999-12-07 | — | — | US | disclosed |
| US-5646289-A | REACTING A 3-CHLORO-1,2,5-THIADIAZOLE WITH ALKALI METAL BIS(TRIALKYL OR ARYLSILYL)AMIDE; DECHLORINATION; TREATING NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY (US) | 1997-07-08 | — | — | US | disclosed |
| WO-1997020819-A1 | COMPOSITION FOR TREATING PAIN | ELI LILLY AND COMPANY (US) | 1997-06-12 | — | — | WO | disclosed |
| WO-1997017962-A1 | METHOD FOR TREATING ANXIETY | ELI LILLY AND COMPANY (US) | 1997-05-22 | — | — | WO | disclosed |
| EP-0774256-A1 | Use of azacyclic or azabicyclic thiadiazole compounds for treating anxiety | ELI LILLY AND COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| CN-1145364-A | Heterocyclic compounds and their preparation and use | LILLY CO ELI (US) | 1997-03-19 | — | — | CN | disclosed |
| WO-1996038431-A1 | PROCESS FOR MAKING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| WO-1996038430-A1 | PROCESS FOR MAKING HETEROCYCLIC COMPOUNDS | ELI LILLY AND COMPANY (US) | 1996-12-05 | — | — | WO | disclosed |
| EP-0745601-A1 | Process for preparing 1,2,5-thiadiazole derivatives | ELI LILLY AND COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |
| EP-0709381-A1 | Heterocyclic compounds and their preparation and use | ELI LILLY AND COMPANY (US) | 1996-05-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115697-A1 | Heterocyclic compounds and their preparation and use | CHRM5, ACHE, CHRM2 | CHRM1 5/4885ALDH1A1 1468/4885MAPT 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.